Patent CA-2402472-A1 (CA)
Title: 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole compounds
Inventor: GHAZAL NABIL B
IPC: A61P25/00
Filed: 2001-03-08
Abstract: A compound of formula (I) where a is a single bond or double bond, and where  R1a, R1b, R2a and R2b are each independently (a) H, Cl, Br, I, F, CN, CF3, OCF3, OR5, CONR5R6, COR5, CO2R5, Y(CH2)mXR5 or YC(O)(CH2)mXR5, where m = 0-3 , Y = CH2, S, O, or NR6, X = CH2, S, O, NR6; (b) (CH2)PAr where p = 0-3 and Ar  is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO2, OR7, CF3, OCF3; SR7, SO2R7, SO2NR7R8, NR7R8,  CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; or (c) linear or branched C1- C8 alkyl, linear or branched C2-C8 alkenyl, linear or branched C2-C8 alkynyl , C3-C8 cycloalkenyl, or C3-C8 cycloalkynyl; wherein any of these groups may b e optionally substituted with one or more of the following: halogen, CN, NO2, COR7, OR7, NR7R8, SR7, CO2R7, CONR7R8 or NR7COR8; and where R3 is (a) H, Cl,  Br, I, F, CN, CF3, OCF3, alkyl, Ar, OR5, SR5, CHO, CONR5R6, COR5, CO2R5, (Y)o(CH2)nXR5, C(O)C(O)NXR5R6, (Y)o(CH2)nC(O)XR5, C(O)(CH2)nXR5, (Y)o(CH2)nN(R6)C(O)NR5R6, where o = 0 or 1, n = 0-3, X = CH2, S, O, or NR6 a nd Y=CH2, S, O or NR6, where Ar is aryl or heteroaryl optionally substituted wi th one or more of the following: H, halogen, CN, NO2, OR7, CF3, OCF3, SR7, SO2R 7, SO2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; (b) linea r or branched C1-C8 alkyl, linear or branched C2-C8 alkenyl, linear or branche d C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C3-C8 cycloalkynyl; wherein any of these groups may be optionally substituted with one or more o f the following: halogen, CN, NO2, COR10, OR10, NR10R8, SR10, CO2R10, CONR10R8  or NR10COR8; and where R4, R5 and R6 are each independently (a) H, linear or  branched C1-C8 alkyl, linear or branched C2-C8 alkenyl, linear or branched C 2- C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C3-C8 cycloalkynyl; wherein any of these groups other than H may be optionally substituted with one or more of the following: halogen, CN, NO2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11 or NR10COR11; or where R5 and R6 are linked to form a 3 to  8 member ring; or (b) (CH2)pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO 2, OR7, CF3, OCF3, SR7, SO2R7, SO2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; and where R7, R8, and R9 are each independently (a) H, linear or branched C1-C8 alkyl, linear or branched C2-C8 alkenyl, linear or branched C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C3-C8 cycloalkynyl groups, wherein any of these groups other than H may be optionally substituted with halogen, CN, NO2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11, NR10COR11, NR10CONR11R12, or where R7, R8, or R9 are link ed to form a ring; (b) (CH2)pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO 2, OR10, CF3, OCF3, SR10, SO2R10, SO2NR10R11, NR10R11, CONR10R11, NR10COR11, NR10CONR11R12, CO2R10, COR10, or R10; and where R10, R11 and R12 are each independently H, linear or branched C1-C8 alkyl, linear or branched C2-C8 alkenyl, linear or branched C2-C8 alkynyl, C3-C8 cycloalky, C3-C8 cycloalkenyl, or C3-C8 cycloalkynyl; or a stereoisomer or pharmaceutically acceptable salt thereof.